Capricor Therapeutics, Inc.

CAPR

US14070B3096

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
4.83 ^USD	+2.33%		+4.32%	-1.23%

Jul. 01	Capricor Therapeutics Joins Russell 3000, Russell 2000 Indexes	MT
Jul. 01	Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2000 Growth Index	CI

Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 3000E Value Index

July 30, 2024

Latest news about Capricor Therapeutics, Inc.

Capricor Therapeutics Joins Russell 3000, Russell 2000 Indexes	Jul. 01	MT
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2000 Growth Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2000 Dynamic Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2500 Growth Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2500 Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 3000 Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 3000E Value Index	Jun. 30	CI
Capricor Therapeutics, Inc. Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy	Jun. 28	CI
Capricor Therapeutics, Inc. Announces for the Treatment of Duchenne Muscular Dystrophy	Jun. 25	CI
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Jun. 11	MT
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise	Jun. 11	MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway	Jun. 11	CI
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy	Jun. 04	CI
Oppenheimer Initiates Capricor Therapeutics at Outperform Rating	May. 17	MT
Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M	May. 13	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting	May. 09	CI
Transcript : Capricor Therapeutics, Inc. - Special Call	Apr. 29
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	Apr. 24	MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	Apr. 24	CI
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Mar. 06	CI
Transcript : Capricor Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	Feb. 29	MT

Chart Capricor Therapeutics, Inc.

Duration

Period

More charts

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Capricor Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.83 USD

Average target price

19.8 USD

Spread / Average Target

+309.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CAPRICOR THERAPEUTICS, INC.	-1.23%	151M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	122B
REGENERON PHARMACEUTICALS, INC.	+16.60%	113B
ARGENX SE	+17.55%	26.22B
BIONTECH SE	-24.33%	19.01B
GENMAB A/S	-19.14%	15.71B
BEIGENE, LTD.	-17.95%	15.22B
WUXI APPTEC CO., LTD.	-46.81%	14.72B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.58B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.84B

Bio Therapeutic Drugs